Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
Brian J. Boyarsky, William A. Werbel, Robin K. Avery, et al.
JAMA (2021) Vol. 325, Iss. 17, pp. 1784-1784
Open Access | Times Cited: 523

Showing 1-25 of 523 citing articles:

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Brian J. Boyarsky, William A. Werbel, Robin K. Avery, et al.
JAMA (2021) Vol. 325, Iss. 21, pp. 2204-2204
Open Access | Times Cited: 951
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
SARS-CoV-2 Variants in Patients with Immunosuppression
Lawrence Corey, Chris Beyrer, Myron S. Cohen, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 6, pp. 562-566
Open Access | Times Cited: 410
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 384
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Queenie Fernandes, Varghese Inchakalody, Maysaloun Merhi, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 524-540
Open Access | Times Cited: 372
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
Ayelet Grupper, Liane Rabinowich, Doron Schwartz, et al.
American Journal of Transplantation (2021) Vol. 21, Iss. 8, pp. 2719-2726
Open Access | Times Cited: 357
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
Iliès Benotmane, Gabriela Gautier, Peggy Perrin, et al.
JAMA (2021) Vol. 326, Iss. 11, pp. 1063-1063
Open Access | Times Cited: 334
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
Liane Rabinowich, Ayelet Grupper, Roni Baruch, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 2, pp. 435-438
Open Access | Times Cited: 321
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
Ayelet Grupper, Nechama Sharon, Talya Finn, et al.
Clinical Journal of the American Society of Nephrology (2021) Vol. 16, Iss. 7, pp. 1037-1042
Open Access | Times Cited: 310
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine
Julian Stumpf, Torsten Siepmann, Tom H. Lindner, et al.
The Lancet Regional Health - Europe (2021) Vol. 9, pp. 100178-100178
Open Access | Times Cited: 286
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
Héctor Rincón-Arévalo, Mira Choi, Ana‐Luisa Stefanski, et al.
Science Immunology (2021) Vol. 6, Iss. 60, pp. eabj1031-eabj1031
Open Access | Times Cited: 265
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A. Kennedy, Simeng Lin, James Goodhand, et al.
Gut (2021) Vol. 70, Iss. 10, pp. 1884-1893
Open Access | Times Cited: 263
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Lee M. Greenberger, Larry A. Saltzman, Jonathon W. Senefeld, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1031-1033
Open Access | Times Cited: 251
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Daniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1345-1350
Closed Access | Times Cited: 232
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients
David Cucchiari, Natalia Egri, Marta Bodro, et al.
American Journal of Transplantation (2021) Vol. 21, Iss. 8, pp. 2727-2739
Open Access | Times Cited: 226
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
Benaya Rozen‐Zvi, Dafna Yahav, Timna Agur, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 8, pp. 1173.e1-1173.e4
Open Access | Times Cited: 203
A correlate of protection for SARS-CoV-2 vaccines is urgently needed
Florian Krammer
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1147-1148
Open Access | Times Cited: 201
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Peter Bergman, Ola Blennow, Lotta Hansson, et al.
EBioMedicine (2021) Vol. 74, pp. 103705-103705
Open Access | Times Cited: 201
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
Rachna T. Shroff, Pavani Chalasani, Ran Wei, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 2002-2011
Open Access | Times Cited: 192
American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3
Jeffrey R. Curtis, Sindhu R. Johnson, Donald D. Anthony, et al.
Arthritis & Rheumatology (2021) Vol. 73, Iss. 10
Open Access | Times Cited: 191
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 635
Open Access | Times Cited: 191
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
Iliès Benotmane, Gabriela Gautier-Vargas, Noëlle Cognard, et al.
Kidney International (2021) Vol. 99, Iss. 6, pp. 1498-1500
Open Access | Times Cited: 181
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
Brian J. Boyarsky, Jake A. Ruddy, Caoilfhionn M Connolly, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 8, pp. 1098-1099
Open Access | Times Cited: 179
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
Yolanda Braun‐Moscovici, Marielle Kaplan, Maya Braun, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1317-1321
Open Access | Times Cited: 179
Page 1 - Next Page

Scroll to top